Immunology

We are advancing innovative science and transformative medicines for people living with inflammatory and autoimmune diseases, including a portfolio of first in class programs and innovative development approaches across inflammatory bowel disease (IBD), respiratory, and rheumatological diseases.

Partnering opportunities we are looking for:

Gastroenterology, Respiratory, Nephrology
- Innate, Adaptive, Fibrosis, Tolerance and Tissue Regeneration Targets

Example partnerships

Telavant

Acquisition to further develop and commercialise RVT-3101, a Phase-3 ready antibody with first-in-class and best-in-disease potential to treat patients suffering from IBD including ulcerative colitis (UC) and Crohn’s Disease and potentially multiple other immune-mediated diseases.

Jnana Therapeutics

Collaboration to develop small molecules against multiple key regulators of cellular metabolism SLC transporters for selected targets in immunology and neurology.

Kiniska

Agreement to further develop and commercialise vixarelimab, a Phase-2 oncostatin-M receptor antibody in fibrotic diseases including IPF.

Your dedicated partnering leads in Immunology

Enza di Modugno

Head of Immunology, CVM & Infectious Diseases, Pharma Partnering

Jean-Eric Charoin

Search & Evaluation Lead Immunology, CVRM, Pharma Partnering

Interested in partnering with us?

If you have an opportunity for collaboration or an interesting technology, or if you have an asset in one of our areas of interest, we would like to hear from you.

Contact our Pharma Partnering Team

More Pharma partnering areas

View all areas

Digital and data
Innovation

We are taking PHC toward a future where treatments are targeted to an individual’s needs and unique genetic profile.

Infectious Diseases
Innovation

We are advancing innovation to combat infectious diseases like HBV, influenza and MDR.

Neurology
Innovation

We focus on advances for neurodegenerative, psychiatric and neurodevelopmental disorders.

Oncology and Haematology
Innovation

We focus on first- and best-in-class therapeutics in molecular targeted therapies and cancer immunotherapy.

Ophthalmology
Innovation

We are focusing on saving people’s eyesight from the leading causes of vision loss through pioneering therapies and cutting- edge research.

Research Technologies
Innovation

We focus on therapeutic modalities and enabling technologies.

Cardiovascular, Renal & Metabolic Disease
Innovation

Roche is committed to making a contribution to areas of huge unmet need and societal burden through transformative science like in cardiovascular and metabolic diseases

Discover more

Infectious diseases
Pharma | Diagnostics

The infectious disease landscape is ever-changing with outbreaks, mutations, emerging pathogens, and growing resistances placing pressures on healthcare systems. Roche is determined to provide relief and care.

Product Development Portfolio
Solutions

Discover our pipeline of Pharmaceutical and Diagnostics developments